Komori
Kaken Pharmaceutical (4521) · PolicyAdvanced

Holding and Reviewing the Rationale for Cross-Shareholdings

First written in FY2019. 5 of 7 entries say "Advanced", first in FY2021. Latest entry: FY2026.

7entries
8years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2021RestatedFY20222019: 120192020: 020202021: 120212022: 120222023: 020232024: 020242025: 020252026: 42026
Same theme, other companies
Reviewing the Rationale for Holding Cross-ShareholdingsA theme 1457 companies write about · 1 as a headwind · 761 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1457 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In May 2024, the company established a policy to reduce cross-shareholdings by the equivalent of 30% from the level at 31 March 2024 within the next 5 years. During the fiscal year under review, all shares in 1 issue and part of the shares in 4 issues were sold, bringing progress against the reduction policy to 56.0%.」

    The company set a policy to reduce cross-shareholdings by the equivalent of 30% within the next 5 years, and reached 56.0% progress through the sale of all shares in 1 issue and part of the shares in 4 issues.
  2. FY2022RestatedAnnual report

    「For the fiscal year under review, a review was conducted at the Board of Directors meeting held in December 2021. During the fiscal year under review, part of the holdings in 1 issue was sold.」

    The company reported the Board of Directors' qualitative and quantitative review of cross-shareholdings and the sale of part of the holdings in 1 issue as results for the fiscal year.
  3. FY2021AdvancedAnnual report

    「For the fiscal year under review, a review was conducted at the Board of Directors meeting held in January 2021. During the fiscal year under review, part of the holdings in 1 issue was sold.」

    The Board of Directors conducted quantitative and qualitative reviews of cross-shareholdings, and part of the holdings in 1 issue was sold. In addition to reviewing the rationale for holding the shares, the company demonstrated progress in reducing them.
  4. FY2019First statedAnnual report

    「The company will hold shares held for purposes other than pure investment only where it determines that doing so will contribute to enhancing the corporate value of the Group.」

    The company disclosed, for the first time as a separate topic, its policy of generally not holding shares for pure investment purposes and having the Board of Directors review whether to hold cross-shareholdings based on business strategy, business relationships, benefits and risks, and other considerations. In the current fiscal year, it determined that holding all issues was appropriate.
Moved together

"Strengthening the New Drug Pipeline and Accelerating Research and Development" moved the same way as this thread, in the same document, in 4 of its 6 moves.

433322★123456
  1. ★This thread
  2. 1Strengthening the New Drug Pipeline and Accelerating Research and Development4×
  3. 2Pharmaceutical licensing in Japan and overseas3×
  4. 3Continuation of R&D investment3×
  5. 4Implementation of Shareholder Returns3×
  6. 5Clinical development pipeline progress2×
  7. 6Maximising Product Value and Strengthening the Sales Platform2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview It last moved in the General Meeting of Shareholders of 2026-05-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Holding and Reviewing the Rationale for Cross-Shareholdings | KAKEN PHARMACEUTICAL CO.,LTD. (4521) | Komori